BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
See today's BioWorld Asia
Home
» South Korea’s Chong Kun Dang invests in startup Biorchestra targeting AD
To read the full story,
subscribe
or
sign in
.
South Korea’s Chong Kun Dang invests in startup Biorchestra targeting AD
Oct. 16, 2019
By
Jihyun Kim
No Comments
HONG KONG – South Korean pharmaceutical company Chong Kun Dang Holdings recently invested KRW5 billion (US$4.1 million) in Biorchestra Co. Ltd., a Korean startup based in Daejeon that aims to develop Alzheimer’s dementia treatment based on microRNA.
BioWorld Asia
Financings
Newco news
Neurology/psychiatric
Series B
Asia-Pacific
